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SUMMARY
Systemic administration of chemotherapeutic agents results in indiscriminate drug distribution and
severe toxicity. Here we report a technology potentially overcoming these shortcomings through en-
capsulation and cancer cell-specific targeting of chemotherapeutics in bacterially derived 400 nm
minicells. We discovered that minicells can be packaged with therapeutically significant concentra-
tions of chemotherapeutics of differing charge, hydrophobicity, and solubility. Targeting of minicells
via bispecific antibodies to receptors on cancer cell membranes results in endocytosis, intracellular
degradation, and drug release. This affects highly significant tumor growth inhibition and regression
in mouse xenografts and case studies of lymphoma in dogs despite administration of minute
amounts of drug and antibody; a factor critical for limiting systemic toxicity that should allow the
use of complex regimens of combination chemotherapy.INTRODUCTION
Severe toxicity remains a major factor limiting cancer che-
motherapeutics. Lack of cancer cell specificity, indiscrim-
inate drug distribution, and rapid clearance necessitate
frequent administration of high doses of chemotherapeu-
tics to elicit a satisfactory clinical response (Langer,
1998). Anticancer antibodies directed to overexpressed
receptors on cancer cells, such as the epidermal growth
factor receptor (EGFR; Nicholson et al., 2001) and HER2/
neu (Rae and Lippman, 2004), are less toxic but do not
possess the potency andwide spectrumantitumor activity
of chemotherapeutic drugs. Efforts are being made to de-velop targeted drug delivery systems (DDSs), such as
stealth liposomes (Medina et al., 2004), nanoparticles
(Brannon-Peppas and Blanchette, 2004; Ferrari, 2005),
andpolymer therapeutics (Duncan, 2003), which encapsu-
late the cytotoxic drug in a vehicle and target it to cancer
cells via tumor cell-surface receptors. However, these
technologies are also hampered by shortcomings, such
as drug leakage in vivo, lack of versatility in terms of pack-
aging a diverse range of different drugs without significant
derivatization, thereby reducing drugpotency, anddifficul-
ties in production scale-up, particularly for nanoparticles.
Here we show that bacterial minicells which are anu-
cleate nanoparticles produced as a result of inactivatingSIGNIFICANCE
Nontargeted cancer chemotherapy is currently associated with severe toxicity. This report describes bacterially
derived nano-sized particles (minicells) for encapsulation of a range of different chemotherapeutic drugs and spe-
cifically targeting the minicells to tumor cell-surface receptors via bispecific antibodies coating the minicells. Re-
ceptor engagement results in minicell endocytosis, intracellular degradation, and drug release. Consequently,
highly significant tumor growth inhibition and regression is achieved despite administration of minute amounts
of drug and antibody. The dramatic increase in therapeutic index may permit the use of multidrug combinations
to achieve an improved outcome for cancer therapy.Cancer Cell 11, 431–445, May 2007 ª2007 Elsevier Inc. 431
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Nano-Sized Particles for Targeted Cancer TherapyFigure 1. Minicell Characterization, Purification, Chemotherapeutic Drug Packaging, and BsAb Targeting
(A) Transmission (Aa, Ab, and Af) and scanning electron microscopy (Ac–Ae) of minicells derived from, S. Typhimurium showing inner and outer mem-
brane structure (Aa), S. Typhimurium with immunogold labeling of surface O-antigen (Ab), minicell budding off parental E. coli (Ac), S. flexneriminicell
and a mix of bacteria and minicells showing relative sizes and abundance (Ad and Ae), and L. monocytogenesminicell and parent cell (Af). Scale bar,
200 nm.
(B) Minicell purification using sequential density gradient centrifugation steps (Ba–Bc) on OptiPrep (6%–20% gradients) showing progressive sepa-
ration and elimination of parental bacteria from the crude minicell preparation (Ba), resulting in significant purification by the third step (Bc).
(C) Fluorescence microscopy images showing differences in size between native E. coli minCDE- strain grown in the absence of NaCl (Ca), and fil-
amentous forms stained with LIVE/DEAD Baclight bacterial viability kit (Molecular Probes; green [live], red [dead] fluorescence) resulting from growth
in 5% NaCl (Cb). Scale bar, 20 mm.
(D) Minicell and bacterial counts during the various steps of minicell purification. (Da) overnight culture, (Db) differential centrifugation, (Dc) 0.45 mm
crossflow filtration, (Dd–Df) successive OptiPrep gradients, (Dg) 2 hr activation of residual bacteria in TSB, (Dh) 2 hr incubation in TSB/5% NaCl, (Di)
antibiotic treatment, (Dj) buffer exchange, (Dk) 0.45 mm dead-end filtration, (Dl) antiendotoxin treatment. Each value is a mean of three samples col-
lected from a separate purification process. Error bars; ± SEM.
(E) Minicells packaged with Dox, showing red autofluorescence of the drug (Ea), or green fluorescence after loading with either BODIPY FL-conju-
gated vinblastine (Eb), or Oregon Green 488-conjugated Pac (Ec). No autofluorescence was observed with empty minicells (data not shown). Scale
bar, 5 mm.
(F) Fluorescent images showing BsAb bound to and coating the surface of drug-packaged minicells. Alexa Fluor 488-conjugated BsAb (green fluo-
rescence) bound to minicellsDox and imaged to show only the green fluorescence of the BsAb (Fa), or to show both the green fluorescent BsAbs, and432 Cancer Cell 11, 431–445, May 2007 ª2007 Elsevier Inc.
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Nano-Sized Particles for Targeted Cancer Therapythe genes that control normal bacterial cell division (De
Boer et al., 1989; Lutkenhaus and Addinall, 1997; Ma
et al., 2004), thereby derepressing polar sites of cell fis-
sion, may provide a solution to these and other obstacles
to cytotoxic drug delivery.
RESULTS
Minicell Generation, Characterization,
and Purification
Genetically definedminCDE chromosomal deletion mu-
tants were generated from Salmonella enterica serovar
Typhimurium (S. Typhimurium), Escherichia coli, Shigella
flexneri, Pseudomonas aeruginosa (Gram), and Listeria
monocytogenes (Gram+) strains. All mutants yielded large
numbers of minicells with a uniform diameter of 400 ±
20 nm (Figure 1A). Like parental bacteria, minicells from
Gram bacteria have a ruffled surface (Figures 1Ac–
1Ae) characteristic of their lipopolysaccharide (LPS)
coat. By contrast, those from L. monocytogenes have
the rigid cell-wall structure (Figure 1Af) expected of
a Gram+ bacterial cell wall. That minicells are derived
from their respective parental bacteria is evident, for ex-
ample, by the ability to immunogold label S. Typhimurium
minicells using an anti-S. Typhimurium O-antigen MAb
(Figure 1Ab).
Complete and reproducible purification of minicells was
achieved using a procedure to eliminate contaminants
such as parent bacterial cells, cellular debris, intracellular
components, free nucleic acids, and free endotoxin. Initial
centrifugation and crossflow filtration steps (Figure 1B) re-
sulted in >90% elimination of bacterial cells. However,
some bacterial cells permeated the filter pores irrespec-
tive of how many serial crossflow filtrations were per-
formed. This was presumably due to some bacterial cells
striking the filter surface perpendicularly and, thus, pass-
ing through it, since the transverse diameter of parent
and minicells is the same, being 400 nm. To eliminate re-
sidual bacterial cells, we took advantage of the fact that
under stress-inducing conditions, such as growth in high
salt, septum formation is incomplete during bacterial cell
division, resulting in filament formation (Mattick et al.,
2000). As shown in Figure 1C, incubation in the presence
of 5% NaCl for 4 hr reliably converted parent bacteria into
filaments of various lengths. This step was thus incorpo-
rated after the initial 0.45 mm crossflow filtration steps
and the resulting filtrate was subjected to 0.2 mm cross-
flow filtration to remove small contaminants like bacterial
membrane blebs, intracellular components, cellular de-
bris, free nucleic acids, and endotoxin. These pass
through the 0.2 mm filter, but minicells and residual bacte-
rial cells are retained. The retentate was then filtered
through a 0.45 mm dead-end filter and both the filtrate
and retentate were subjected to FACS analysis. This re-vealed that filaments were only present in the retentate
and, thus, were entirely eliminated from the filtrate. As a re-
sult, the final minicell preparation was sterile as confirmed
by plating the entire preparation on growth agar plates and
incubating it overnight at 37C to demonstrate the ab-
sence of bacterial colonies. Additionally, preparations
were grown for 14 days in thioglycolate broth to demon-
strate the absence of any slow-growing organisms. Mini-
cells were enumerated by FACS analysis, with a yield of
approximately 5 3 1010 to 1011 minicells (Figure 1D)
from a 6 L starting culture being routinely obtained. We
also demonstrated that minicells can be lyophilized in
a cryoprotectant and stored for at least 4 months (the lon-
gest period tested) and then successfully reconstituted
(data not shown).
Efficient Packaging of Chemotherapeutic Drugs into
Minicells, Drug Quantitation, and Targeting Using
Bispecific Antibodies
To determine if minicells can be packaged with chemo-
therapeutic drugs down a concentration gradient despite
an intact bilayer membrane, preparations of purified mini-
cells (109) derived from S. Typhimurium and E. coli
minCDE mutants were separately incubated with the
chemotherapeutic drugs, doxorubicin (Dox; 60 mg/ml), Or-
egon Green 488-conjugated paclitaxel (Pac; 100 mg/ml),
and BODIPY FL-conjugated vinblastine (Vin; 100 mg/ml).
Minicell drug loading was evident with all drugs, either
by the red autofluorescence of Dox (Figure 1Ea) or green
fluorescence of the minicells packaged with vinblastine
or paclitaxel (Figures 1Eb and 1Ec). Targeting of minicells
was achieved using bispecific antibodies (BsAb), in which
one arm recognizes the O-antigen component of the mini-
cell surface LPS and the other, a cell-surface receptor
specific for the mammalian cell to be targeted, for exam-
ple, EGFR (El-Rayes and LoRusso, 2004) or HER2/neu re-
ceptor (Slamon et al., 1987) on breast and ovarian cancer
cells, respectively. Linkage of these two antibodies via
their Fc regions was achieved by the use of protein A/G.
Drug loading and BsAb linkage were confirmed as shown
in Figures 1E and 1F. Drug-packaged and targeted mini-
cells were designated EGFRminicellsDox, for example, for
those packaged with Dox and targeted using an anti-
EGFR BsAb, or HER2minicellsPac, for those packaged
with Pac and targeted using an anti-HER2 BsAb. In addi-
tional studies, we found that minicells could also be pack-
aged with other chemotherapeutic drugs, including car-
boplatin, cisplatin 5-fluorouracil (5-FU), gemcitabine,
irinotecan, and kinesin spindle protein inhibitor monastrol.
To determine the kinetics of minicell drug packaging, the
amount of drug packaged per minicell in response to vary-
ing concentrations of drug in the incubation solution or
varying times of incubation were evaluated. As shown in
Figure 2A, drug packagingwas dependent on, and directlythe red autofluorescing Dox within the minicell (Fb). In (Fc), minicells packaged with Oregon Green 488-conjugated Fluoro-Pac (green fluorescence)
were coated with Alexa Fluor 594-conjugated BsAb (red fluorescence). The intense yellow fluorescence shown is due to the overlay of the red surface
(BsAb) and green cytoplasm (Pac). Scale bar, 1 mm.Cancer Cell 11, 431–445, May 2007 ª2007 Elsevier Inc. 433
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Nano-Sized Particles for Targeted Cancer TherapyFigure 2. Drug Quantitation in Minicells, Drug Efflux, and Intracellular Breakdown of Minicells
(A) Quantitation of minicell loading when incubated in the presence of different drug concentrations (Aa, Ac, and Ad) and for different times (Ab). In (Aa,
Ac, and Ad), minicells were incubated for 1 hr with different concentrations of Dox, Pac, or cisplatin. Drug loading was determined after extraction
fromminicells and quantitation by HPLC and fluorescence detection or LC-MS/MS. In (Ab), minicells were incubated with Dox (60 mg/ml) for the times
shown (n = 6). To evaluate drug efflux after loading, minicells were incubated in an external concentration of Dox (200 mg/ml). The minicellsDox were
incubated in BSG for 72 hr at 4C and Dox was extracted and quantitated from samples (triplicate) at the time points shown (Ae). Despite prolonged
incubation in BSG no drug efflux was observed. Error bars, ± SEM.
(B) Phagocytic uptake of nontargeted minicells by macrophages. S. Typhimurium-derived minicells were incubated with mouse macrophage cells
(RWA 264.7) at a ratio of 100:1. At the times indicated, the cells were subjected to immunogold labeling using anti-O-antigen primary, and gold
(10 nm)-conjugated anti-mouse secondary antibody followed by TEM. Immunogold-labeled minicells are evident on the macrophage cell surface
(Ba). At later times numerous minicells can be seen within intracellular vacuoles (Bb and Bc) where disruption of their cell walls is evident. Scale
bar, 500 nm.434 Cancer Cell 11, 431–445, May 2007 ª2007 Elsevier Inc.
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solution (Figures 2Aa, 2Ac, and 2Ad), and the time of incu-
bation (Figure 2Ab). With the incubation of 5 3 108 mini-
cells for 1 hr with 250 mg/ml Dox, 100 mg/ml Pac, or
400 mg/ml cisplatin, the amount packaged was 4.8 mg,
0.25 mg, and 0.1 mg, respectively. This equates to10mil-
lion, 220,000, and 614,000 drug molecules packaged per
minicell, respectively. To examine drug efflux, minicellsDox
were incubated for up to 72 hr in buffered saline gelatin
(BSG) before drug extraction and quantitation. This con-
firmed a lack of drug efflux (Figure 2Ae). These findings
therefore show that minicells can be readily packaged
with chemotherapeutic drugs, whether they be hydrophilic
(irinotecan), hydrophobic (Pac, cisplatin, carboplatin,
monastrol), or amphipathic (Dox, vinblastine, 5-FU), and
that diffusion across the minicell phospholipid bilayer-
membrane is essentially unidirectional; efflux not being
observed even with extensive minicell washing and incu-
bation in drug-free solution.
Intracellular Processing of Minicells and Targeted
Minicell-Mediated Drug Delivery to Cancer Cells
In Vitro
Following internalization, TEM studies of minicell-treated
cancer cells and mouse macrophage cells showed that
the minicells were localized in intracellular vacuoles
(Figure 2B). As many as five to eight minicells were local-
ized in a single vacuole, with a single cell carrying as many
as 40 to 50 minicells. At later time points, minicell integrity
was lost and membrane fragments carrying LPS were
evident within vacuoles, indicating minicell breakdown
(Figure 2Bc).
To determine if BsAb-targeted, drug-packaged mini-
cells can deliver bioactive drug intracellularly into human
cancer cells, we incubated MDA-MB-468 human breast
adenocarcinoma cells with EGFRminicellsDox (10
9), and
monitored their fate over 48 hr by confocal microscopy.
As controls, CMVminicellsDox where the BsAb is directed
to an irrelevant antigen, CMV (cytomegalovirus capsid
protein), and non-Dox-packaged EGFRminicells, were
also studied.
As shown in Figure 3A, within 4 hr, only MDA cells
treated with EGFRminicellsDox and
EGFRminicells showed
large numbers of minicells intracellularly (green fluores-
cence due to BsAb attached to the minicell surface;
Figures 3Ab and 3Am). Since the nontargeted minicells
and CMVminicellsDox did not adhere to the MDA cell sur-
face and were not internalized (absence of green or red
fluorescence; Figure 3Ak), it is likely that the BsAb-
targeted EGFRminicellsDox and
EGFRminicells gained entry
into the MDA cell cytoplasm via EGFR-mediated endocy-
tosis. At 4 hr, the minicells were confined to the MDA cell
cytoplasm since the overlaid image (Figure 3Ae) showed
that the nucleus remained blue, similar to the DAPI-
stained nucleus seen in Figure 3Ad. Additionally, in the
overlaid image (Figure 3Ae), colocalization of the minicell-
and Dox-associated green and red fluorescence, respec-
tively, showed yellow fluorescence in the MDA cell cyto-
plasm suggesting that the drug had not yet been releasedfrom the minicells. In contrast, by 16 hr to 24 hr, the MDA
nucleus showed intense diffuse red fluorescence (Fig-
ure 3Ah; compare with Figure 3Ac) and the minicell-
associated green fluorescence had significantly de-
creased (compare Figures 3Ab and 3Ag) only in the
EGFRminicellsDox-treated cells. Nuclear presence of Dox
was confirmed in the overlaid images, which showed
violet fluorescence (Figure 3Aj) due to colocalization of
the blue DAPI stain (Figure 3Ai) and red Dox fluorescence
(Figure 3Ah), while all other overlaid images showed only
the blue fluorescence of DAPI (Figures 3Al and 3An).
This suggested that the Dox had now been released
from the minicell cytoplasm and had translocated to the
nucleus. By 48 hr, gross abnormalities in cellular integrity,
nuclear disorganization, and cell death were readily ap-
parent (Figure 3Ao), presumably due to the cytotoxic ef-
fect of Dox within the nucleus. In contrast, minicell attach-
ment to MDA cells was not observed at 4 or 24 hr with
CMVminicellsDox (Figures 3Ak–3Al; note the lack of green
or red fluorescence), whereas attachment but not Dox
was observed with EGFRminicells (Figures 3Am and 3An;
note perinuclear green fluorescence, but lack of red or vi-
olet fluorescence). With both these controls, cell integrity
was unaltered, even at 48 hr (data not shown). Specificity
of receptor attachment via BsAb-targeted minicells was
evaluated by coincubating MDA cells with specifically
(EGFRminicells) and nonspecifically (CD33minicells) tar-
geted minicells where the BsAbs were conjugated to
Alexa Fluor 488 fluorescent dye. Only the EGFRminicells
specifically adhered (>95%) to MDA cells (Figure 3B). Cy-
totoxicity of minicell-delivered Dox was also apparent
when cell viability was evaluated quantitatively using the
colorimetric MTT assay (Cory et al., 1991). Cell death
was similar for MDA cells incubated with EGFRminicellsDox
or free Dox, whereas viability remained largely unchanged
when cells were treated with nontargeted minicellsDox
(Figure 3C).
BsAb-Targeted, Minicell-Mediated
Chemotherapeutic Drug Delivery to Human Breast,
Leukemia, and Ovarian Cancer Cell Xenografts
In Vivo
We next investigated if receptor-targeted, drug-packaged
minicells could deliver Dox to human cancer xenografts
in vivo. As shown in Figure 4A, compared to control groups
that received intravenous (i.v.) or intratumoral (i.t.) nontar-
geted minicellsDox, or BsAb (anti-O antigen/anti-EGFR)
plus free Dox, administration of EGFRminicellsDox to mice
with MDA xenografts (tumor volume 50–70 mm3) re-
sulted in highly significant inhibition of tumor growth.
Failure to see tumor growth inhibition with minicellsDox in-
dicates that BsAb-mediated targeting is essential. Impor-
tantly, tumor regression was readily apparent when ani-
mals with very large tumors (800–1000 mm3), which
had developed following treatment with nontargeted mini-
cellsDox for 7 weeks (Figure 4A, day 63), were switched to
treatmentwith EGFRminicellsDox. This resulted in adramatic
reduction in tumor volume to 100–150 mm3 after only 6
days (Figure 4A, day 79), which was maintained for theCancer Cell 11, 431–445, May 2007 ª2007 Elsevier Inc. 435
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Nano-Sized Particles for Targeted Cancer TherapyFigure 3. Dynamics of Minicell Attachment, Endocytosis, Breakdown and Drug Delivery, and Cytotoxicity
(A) MDA-MB-468 cells were treated with EGFRminicellsDox,
EGFRminicells, or CMVminicellsDox and visualized by confocal microscopy over 48 hr. MDA
cell membrane was visualized with Alexa Fluor 647-conjugated anti-EGFRmAb (violet fluorescence), minicells by Alexa Fluor 488-conjugated anti-O
antigen/anti-EGFR or /anti-CMV BsAbs (green fluorescence) attached to their surface, Dox by its red autofluorescence, and MDA nuclei by DAPI
staining (blue fluorescence). The images shown are for MDA cells treated with EGFRminicellsDox (4 hr, Aa–Ae; 24 hr, Af–Aj; 48 hr, Ao),
CMVminicellsDox
(4 hr, Ak; 24 hr, Al), and EGFRminicells (4 hr, Am; 24 hr, An). Overlaid images for EGFRminicellsDox include, (Ae), a composite of Aa to Ad, and (Aj), a com-
posite of Af to Ai. The CMVminicellsDox and
EGFRminicells images are composites corresponding to those for EGFRminicellsDox (Ae and Aj), except that
the individual images showing EGFR-, BsAb-, Dox-, and DAPI-fluorescence are not shown. Only EGFRminicellsDox and
EGFRminicells specifically at-
tached and internalized in MDA cells (Ab, Am). Postinternalization, the minicells are broken down to release Dox, which is translocated to the nucleus
(Ah, Aj). After 48 hr, loss of cellular and nuclear integrity is seen (Ao). Scale bar, 20 mm.
(B) FACS analysis of MDA cells incubated for 30 min with specifically targeted EGFRminicells or nonspecifically targeted CD33minicells. The anti-EGFR
and CD33 BsAbs were labeled with Alexa Fluor 488 (Molecular Probes) and the result showed that greater than 99% of the cells fluoresced only when
coincubated with EGFRminicells.
(C) Cytotoxicity of Dox delivered to MDA cells by EGFRminicellsDox was evaluated by incubating cells (10
7) with either free Dox (50 ng/ml), 109
minicellsDox, or
EGFRminicellsDox, (10
9 minicells contained 900 ng Dox) and then monitored for viability. Error bars, ± SEM.rest of the study. An additional beneficial effect of Dox
delivery via targeted minicells is the markedly smaller
amounts of drug required to affect tumor growth inhibi-
tion/regression with minicell-packaged delivery versus
free drug administration. Thus, even 1875 times the
amount of free Dox (150 mg) versus minicell-packaged
Dox (0.08 mg) did not produce comparable xenograft
growth inhibition (see for example Figure 4A, day 63, G2,
G3, or G4 versus G7 or G8). Finally, phlebitis, thought to
result from extravasation of drug and leading to local
site vesicant/tissue damage, a well-recognized complica-
tion of i.v. Dox (Ewesuedo and Ratain, 2003) and one that
was clearly evident in animals treated here with free drug
(Figure 4E), was not observed in any of the mice treated
with minicellsDox.
We investigated if a hydrophobic drug like Pac could
also be delivered effectively to mice with MDA xenografts
by repeating the studies shown in Figure 4A, except using
EGFRminicellsPac as the experimental treatment. Similar
highly significant inhibition of tumor growth (Figure 4B,436 Cancer Cell 11, 431–445, May 2007 ª2007 Elsevier Inc.p < 0.0003 and p < 0.0006 for the G7 and G8 groups ver-
sus all others, respectively) was evident both in mice
treated i.v. or i.t. with EGFRminicellsPac. This was despite
an 8000-fold lower Pac dose being administered via
EGFRminicellsPac (0.05 mg/mouse) compared to free
Pac (400 mg/mouse). Moreover, none of themice treated
with either EGFRminicellsDox or
EGFRminicellsPac showed
signs of toxicity, such as weight loss, fever, lethargy,
loss of appetite, or death.
To investigate if specific targeting of tumor cells via
BsAb-coated, drug-packaged minicells was essential for
the observed antitumor effects, xenografts were estab-
lished using A549 lung carcinoma cells that overexpress
EGFR (448,000/cell) but not the plasma membrane
marker, CD33 (Figure 4C). These mice were given a range
of control treatments (Figure 4D; G1 to G10 mice) and two
experimental treatments with EGFRminicellsPac (G11) and
CD33minicellsPac (G12). Consistent with an essential role
of the targeting BsAb, CD33minicellsPac had no antitumor
effect, whereas EGFRminicellsPac were highly effective in
Cancer Cell
Nano-Sized Particles for Targeted Cancer TherapyFigure 4. Tumor Xenograft Treatments with BsAb-Targeted, Dox- or Pac-Packaged Minicells, and Safety in Mice
Inhibition/regression of tumor growth in mice with MDA-MB-468 xenografts via EGFR- or CD33-targeted, Pac- or Dox-packaged minicells, demon-
stration that BsAb-mediated targeting of minicells to tumor cells is necessary for antitumor effects and safety of minicell-delivered Dox. Error bars for
all graphs, ± SEM.
(A) Mice (n = 11/group) bearing MDA xenografts were treated i.v. or i.t. with either free Dox (7.5 mg/gm,150 mg/mouse) or BsAb (anti-O-antigen/anti-
EGFR) plus free Dox (7.5 mg/gm, i.v. only), minicellsDox (10
8), or EGFRminicellsDox (10
8); the Dox-packaged minicells carrying 0.08 mg Dox per dose.
Inhibition of tumor growth is evident by day 56 with EGFRminicellsDox (p < 0.0004 for tumor volume versus all other treatments), but not with the other
treatments. At day 63, the groups treated with nontargeted minicellsDox were switched to
EGFRminicellsDox treatment (open blue triangles). This re-
sulted in rapid and highly significant tumor regression (p < 0.001 for tumor volume at day 69 versus day 63).
(B) The studies were performed as detailed in Figure 4A, except that the animals were given either minicells packaged with Pac (0.05 mg/dose) or free
Pac (20 mg/gm,400 mg/mouse). Inhibition of tumor growth is evident by day 25 in the groups receiving EGFRminicellsPac (p < 0.0004 for tumor volume
versus all other treatments), but not in the other groups.
(C) Receptor quantitation study on A549 lung carcinoma cell line where EGFR, HER-2/neu, and CD33 were quantitated. As negative controls, anti-
CMV MAb was used along with untreated cells. Cells were treated with the various primary antibodies and a Phycoerythrin (PE)-labeled secondary
antibody followed by FACS analysis. Receptor quantitation was carried out using the Quantum PE MESF kit (Molecules of Equivalent Soluble
Fluorochrome; Bang Labs). Mean receptor numbers were EGFR (447,515) and HER2 (1686 for 50% cells and 917,352 for the remaining
50%). The cells did not stain for CD33 or CMV.
(D) A549 xenograft with a range of different controls including free Pac (G2), specifically and nonspecifically targeted BsAbs followed by free Pac (G3
and G4), nontargeted, Pac-packaged minicells (G5), nontargeted minicells followed by free Pac (G6), EGFR-targeted minicells (G7) and followed by
free Pac (G8), nonspecifically targeted minicells (G9) and followed by free Pac (G10) as shown in the figure. The experimental groups consisted of
EGFRminicellsPac (G11; A549 overexpresses EGFR) and
CD33minicellsPac (G12; A549 does not express CD33). Inhibition of tumor growth was evident
in G11 mice and not in any other group including G12. On day 42, when the tumor volume was 400–500 mm3, the treatment of G12 mice was
changed to EGFRminicellsPac which resulted in rapid tumor regression (p < 0.0003 at day 56 between G12 versus all groups).
(E) Safety of minicell-packaged i.v. Dox delivery. Mice given free Dox injected i.v. into the tail vein developed severe phlebitis (a; arrow and bracketed
region of the tail). However, i.v. minicellsDox and
EGFRminicellsDox were well tolerated in all animals, without inflammatory reaction (b).Cancer Cell 11, 431–445, May 2007 ª2007 Elsevier Inc. 437
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Nano-Sized Particles for Targeted Cancer TherapyFigure 5. Antitumor Effects in Tumor Xenografts, Dose Response, and Stability
Antitumor effects via S. Typhimurium or E. coli-derived HER2minicellsDox, comparison of minicellsDox versus liposomalDox, minicellsDox dose response,
minicellsDox stability following lyophilization and antitumor effects in promyelocytic leukemia cell xenografts following
CD33minicellsDox treatment.
Error bars for all graphs, ± SEM. All xenografts have 11 mice per group. Arrowheads below the abscissae indicate the days that minicell treatments
were given.
(A) Mice with HL-60 promyelocytic leukemia cell xenografts were treated i.v. with 53 108 CD33minicellsDox carrying 1 mg Dox/dose. MinicellsDox were
used as controls. Inhibition of tumor growth was evident by day 33 for animals treated with CD33minicellsDox (p < 0.0001 for tumor volume in G3 mice
versus all controls).
(B) Inhibition of tumor growth in mice with SKOV3 ovarian cancer cell xenografts treated with Dox-packagedminicells derived from S. Typhimurium or
E. coli and targeted to the HER2 receptor. Mice with SKOV3 xenografts were treated i.v. with either free Dox (7.5 mg/gm;150 mg/mouse), BsAb (anti-
O-antigen/anti-HER2/neu) plus free Dox (7.5 mg/gm, i.v. only), minicellsDox (10
8), or HER2minicellsDox (10
8); the minicells carrying 0.08 mg Dox per dose.
Inhibition of tumor growth is evident by day 24 for animals treated with HER2minicellsDox derived from either S. Typhimurium or E. coli (p < 0.0009 and
< 0.0014 for tumor volume versus all controls respectively).
(C) Comparison of liposomal-Dox (DOXIL) and EGFRminicellsDox treatment of mice with MDA xenografts. G2 mice received a high dose of DOXIL
(100 mg dox/dose) while G3 mice received DOXIL in a dose that provided the same amount of Dox (1 mg) as the G4 mice that were treated with
EGFRminicellsDox. Highly significant tumor growth inhibition (p < 0.0001) was achieved in G2 and G4 mice, but not in G3.
(D) Dose-related effects of i.v. EGFRminicellsDox on tumor growth. Mice with MDA xenografts were treated with 10
6, 107, or 108 doses of
EGFRminicellsDox; each minicell dose carrying the amount of Dox indicated. Note that tumor volumes in all treated groups are significantly less by
day 42 (p < 0.001) than in the untreated (tumor only) control animals.
(E) Stability of the drug-packaged and BsAb-targetedminicells. Mice withMDA xenografts were treatedwith either freshly prepared or lyophilized and
reconstituted EGFRminicellsDox. Both treatment groups (G2 and G3) showed similar significant degrees of tumor growth inhibition compared to the
control group (G1), by day 25 (p < 0.0001).tumor stabilization. This was further confirmed when G12
mice treated with CD33minicellsPac were switched to treat-
ment with EGFRminicellsPac on day 46 when their tumors
were 400–500 mm3. This resulted in rapid tumor
regression.
Since it is possible that anti-EGFR and anti-HER2/neu
antibodies may elicit antiangiogenic effects (Petit et al.,438 Cancer Cell 11, 431–445, May 2007 ª2007 Elsevier Inc.1997; Izumi et al., 2002), we carried out an HL-60 promye-
locytic leukemia cell xenograft study in which minicellsDox
were targeted to an HL-60 cell-surface marker CD33.
Antibodies to this cell-surface marker are not known to
exhibit antiangiogenic effects. Highly significant tumor
growth inhibition was also observed in these mice
(Figure 5A), suggesting that suppression of tumor growth
Cancer Cell
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antiangiogenic mechanisms. However, further work will
be required to rule out the possibility that EGFR and
HER2-targeted minicells have both direct and antiangio-
genic effects. We also investigated if drug-packaged
minicells could be used to treat SKOV3 ovarian cancer
xenografts targeted via their overexpressed HER2/neu
receptor. Additionally, in these studies minicells derived
from both S. Typhimurium and E. coli minCDE strains
were tested for efficacy of drug delivery. The experimental
groups received HER2minicellsDox, and again, significant
antitumor effect was seen in mice treated with either
S. Typhimurium- or E. coli-derived HER2minicellsDox
(Figure 5B).
Comparison with Liposomal-Dox, Dose Response,
and Minicell Stability
We compared the antitumor activity of liposomal-Dox
(DOXIL) with that of EGFRminicellsDox. Mice with MDA xe-
nografts were treated i.v. with DOXIL carrying high (100
mg) or low (1 mg) doses of Dox; the latter being the dose
also given to animals treated with EGFRminicellsDox. Only
the dose of DOXIL providing a 100-fold higher amount of
Dox produced the same degree of tumor growth-inhibition
as that seen with the EGFRminicellsDox treatment that pro-
vided only 1 mg of Dox (Figure 5C).
We also investigated the dose of targeted, drug-pack-
aged minicells required to achieve a significant antitumor
effect, using 106, 107, and 108 EGFRminicellsDox, each
packaged with two different amounts of Dox and given
i.v. to mice with MDA xenografts. Figure 5D shows that
a dose of 108 EGFRminicellsDox was most effective in
achieving tumor growth inhibition, whether carrying 85 ng
or 660 ng of drug. The 107 and 106 doses of >EGFRmini-
cellsDox were also effective, with the former being more
effective than the latter. Thus, there is a clear relationship
between minicell dose and antitumor efficacy. To
determine the stability of the complete therapeutic entity,
EGFRminicellsDox were lyophilized in an iso-osmotic cryo-
protectant, trehalose, reconstituted in sterile physiological
saline and injected i.v. into mice with MDA xenografts. An-
other group of mice were given freshly prepared EGFRmini-
cellsDox. Both preparations were shown to be equally ef-
fective in stabilizing tumor growth (Figure 5E).
Minicell Biodistribution in Mice, Case Studies in NHL
Dogs, and Minicell Safety in Pigs
The biodistribution of i.v.-administered minicells bearing
125I-labeledBsAbswas studied in nudemicewithMDAxe-
nografts that overexpress EGFR. These studies revealed
that at 2 hr posttreatment, 30% of the EGFRminicells
were localized in the tumor, as compared to only 1.3%
of nonspecifically targeted CMVminicells (Figure 6Aa). In
addition, in animals given radioiodinated BsAb alone
(EGFRBsAb or CMVBsAb), only 3 and 2.2%, respectively,
of the radiolabel was localized in the tumor at 2 hr. By 6
(Figure 6Ab) and 24 hr (Figure 6Ac),4.6%and0.5%, re-
spectively, of specifically targeted EGFRminicells remained
in the tumors. These data suggest that in contrast to non-specifically targeted CMVminicells, EGFRminicells are not
only localized but are concentrated in the tumor microen-
vironment. This likely results from rapid extravasation of
EGFRminicells from the circulation via the leaky vasculature
of the tumor (passive targeting), followed by engagement
of tumor cell-surface EGFRs (active targeting), adherence,
and endocytosis. While nonspecifically targeted CMVmini-
cells may also rapidly extravasate from the circulation,
they are not retained in the tumors as they are unable to
target EGFRs and are washed out after tumor isolation
and extensive saline washing of the tissue.
Biodistribution of minicell-packaged drug was deter-
mined following i.v. administration of EGFRminicellsDox,
nontargeted minicellsDox, or free Dox to nude mice with
MDA xenografts (tumor volume between 140 and 170
mm3). As shown in Figure 6B, at 6 hr, 30% of the Dox
dose administered by the EGFRminicellsDox was found in
the tumors, as compared to only 1% of free Dox and
0.34% of that in minicellsDox. Moreover, similar results
were observed in animals with much larger tumors
(400–600 mm3), in which 28.1% of the Dox dose in
EGFRminicellsDox was found in the tumors at 6 hr, as com-
pared to only0.21% of that in nontargeted, minicellsDox,
and 1.8% for free Dox. Plasma concentration of Dox at
both time points was undetectable. Thus, targeted
minicell delivery provides at least a 30-fold enrichment in
tumor drug delivery. At 6 hr, biodistribution to the liver
and spleen was higher with the EGFRminicellsDox and mini-
cellsDox compared to free Dox and showed a slow de-
crease by 24 hr. At 6 hr, the biodistribution to the lungs
was also found to be higher with EGFRminicellsDox admin-
istration. However, it was rapidly cleared from this tissue,
as was evident by the marked fall in lung Dox-levels at
24 hr. At 2 hr, minicell uptake in the liver (Figure 6Aa) for
EGFRminicells and CMVminicells was not significantly differ-
ent (p = 0.095), suggesting that both types of minicells
accumulate in the liver at similar levels. The data are fur-
ther confirmed in Figure 6B where the Dox concentration
in the liver at 6 hr and 24 hr post-i.v. administration of mini-
cellsDox or
EGFRminicellsDox is similar.
The biodistribution studies reveal early localization of
theminicells in the tumor and rapid clearance from all sites
within 24 hr. These results are similar to other observa-
tions with noncoated nanoparticles (Jun et al., 2005) and
is likely to be due to the passive targeting via the enhanced
permeation and retention effect of the tumor-associated
leaky vasculature.
The anticancer efficacy of the minicells was evaluated
in two case studies in which dogs with advanced (stage
4) T cell non-Hodgkin’s lymphoma (NHL) were treated
i.v. with anti-canine-CD3minicellsDox. One dog (4 kg) received
a total of five doses over 35 days, and the other dog (40 kg)
received seven doses over 48 days providing total
amounts of Dox of 24 mg and 584 mg, respectively. Both
dogs demonstrated marked tumor regression, as evident
by highly significant reductions in lymph node size
(Figure 7A), with the smaller dog also developing tumor
lysis syndrome (hyperkalemia) by day 37 (data not shown).
The proinflammatory cytokines, TNFa (Figure 7B) and IL-6Cancer Cell 11, 431–445, May 2007 ª2007 Elsevier Inc. 439
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Xenografts
Error bars for all graphs, ± SEM.
(A) Biodistribution of EGFRminicells and CMVminicells (3.23 109 minicells per dose) bearing 125I-labeled BsAbs determined following their i.v. admin-
istration to nudemice carryingMDA xenografts. Tumor, spleen, liver, kidney, and lungwere excised from fivemice per treatment at 2, 6, and 24 hr, and
radioactivity was determined by g spectroscopy. (Aa) At 2 hr posttreatment,30% of the 125I-labeled EGFRminicells were localized in the tumor com-
pared to only 1.3% of the 125I-labeled CMVminicells, 3% of the EGFRBsAb, and 2.2% of the CMVBsAb. (Ab and Ac) The various treatments were
rapidly cleared from the tissues by 24 hr (Ab) and 48 hr (Ac).
(B) Biodistribution of Dox in vivo following i.v. administration of free dox (G1, 150 mg/dose), nontargeted minicellsDox (G2),
EGFRminicellsDox (G3) to
nude mice carrying MDA-MB-468 xenografts. Minicells (5 3 109/dose) carrying 74 mg Dox were administered. Posttreatment, three mice from
each group were euthanized at 6 hr and 24 hr. From eachmouse, the tumor, spleen, liver, kidney, heart, and lung were excised and dox concentration
was determined by HLPC and LC-MS/MS. At 6 hr EGFRminicellsDox delivered30% of the total Dox dose administered to the tumor compared to that
delivered with free Dox (1%) or minicellsDox (0.34%).(data not shown), did not increase in either dog despite re-
peated administration of CD3minicellsDox. Surprisingly,
anti-S. Typhimurium LPS titers also remained at back-
ground levels (Figure 7C), and evaluations of hematologi-
cal indices, blood chemistries body weight, temperature,
and urine analyses did not show any adverse changes
with minicell administration (data not shown). The only
mild potentially adverse response was a 0.5C–1C rise
in temp postinjection. This was not sustained and had re-
turned to normal by 4 hr postinjection.
We also evaluated the safety of i.v. administered mini-
cells in three healthy pigs. Despite five successive i.v.
doses of 5 3 109 minicells, the pigs did not show ad-
verse effects, as determined from evaluations of hemato-
logical indices and blood chemistries, as well as by as-
sessment of respiratory rate, food intake, growth, the
levels of proinflammatory mediators (TNFa, IL-6; Figures
7D–7E), and the acute phase reactant, haptoglobin
(Figure 7F). Minor, variable increases in TNFa levels
were observed at 1.5 hr after the administration of the third
to fifth doses of minicells, which returned to baseline by 4–
24 hr (Figure 7D). A weak serum anti-O antigen response
was observed (Figure 7G) with the peak titer being evident
after the second dose, which then decreased to even
lower levels despite a further three doses. Postinjection,440 Cancer Cell 11, 431–445, May 2007 ª2007 Elsevier Inc.the pigs developed a minor fever but was not sustained
and returned to normal within 2 hr.
DISCUSSION
We have developed a robust and versatile system for
in vivo drug delivery using minicells, a bacterially-derived
microreservoir-type carrier. These anucleate minicells
(400 nm diameter) can be readily produced in high yield
from both Gram+ and Gram organisms and purified free
of parental bacteria, membrane blebs, nucleic acids, cel-
lular debris, and free endotoxin, using commercially avail-
able filters. Minicells are stable and can be targeted to
cancer cells in vitro and in vivo with high specificity and
can, thus, be delivered in high concentration in vivo with-
out toxicity. This was evident by the lack of a febrile re-
sponse, weight loss, or skin/fur changes, etc. in themurine
xenograft model, as well as by the lack of any abnormali-
ties in blood chemistries (electrolytes, renal, and hepatic
function) in pigs given repeated i.v. doses.
Minicells can package a range of anticancer chemo-
therapeutic drugs, such as doxorubicin, paclitaxel, irinote-
can, 5-fluorouracil, cisplatin, carboplatin monastrol, and
vinblastine despite their disparate structure, charge,
hydrophobicity, and solubility. In contrast, attempts to
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Error bars for all graphs; ± SEM.
(A) A dog (40 kg) with T cell NHL treated i.v. with Dox-packaged, canine CD3 T cell surface receptor-targeted minicells. Seven i.v. injections of
CD3minicellsDox providing a total Dox dose of 584 mg were given. Tumor volume measurements of lymph nodes in the various areas indicated (de-
termined as described in the Experimental Procedures) revealed significant regression as early as 15 days posttreatment (p < 0.02), which was highly
significant by days 28 and 37 (p < 0.0001 and 0.0009, respectively). When the dog was left untreated between days 28 and 43, the nodes increased in
size but again regressed with additional doses of CD3minicellsDox on days 43 and 48 (p < 0.02 versus the node sizes at day 43) suggesting that repeat
dosing did not result in immune response-mediated exclusion of subsequent doses.
(B) Absence of TNFa response in the NHL dog in (A) treated with CD3minicellsDox.
(C) Absence of an increase in anti-S. Typhimurium LPS titers in the NHL dog in (A) given seven repeat doses of CD3minicellsDox. Note that the initial titer
was determined before the first administration of CD3minicellsDox.
(D–G) TNFa (D), IL-6 (E), serum haptoglobin ([F]; level at which acute phase reaction occurs in pigs is shown by a dotted line) and anti-S. Typhimurium
O-antigen antibody (G) responses in healthy pigs given five repeat doses (doses 1 to 5 in each graph are color coded) of 5 3 109 minicells.package these drugs in other DDSs, such as liposomes,
has required specific and significant alterations to either
the drug or vector, resulting in compromised potency.
The phenomenon of solute movement into bacterial cells
and the extrusion of noxious solutes from bacterial cells
has been studied for over 3 decades and is well under-stood. Drug loading of minicells is likely by diffusion
down a concentration gradient with entry via nonspecific
porin channels (Nikaido, 1996, 2003; Poole, 2002) in the
outer membrane. Detailed studies of porins have revealed
charged residues within the channels resulting in a trans-
versal electric field that separates polar and nonpolarCancer Cell 11, 431–445, May 2007 ª2007 Elsevier Inc. 441
Cancer Cell
Nano-Sized Particles for Targeted Cancer Therapysolutes. Polar solutes are thought to be oriented in the field
during permeation, which therefore becomes a fast one-
dimensional diffusion process (Schulz, 1993). Nonspecific
diffusion of hydrophobic solutes across the outer mem-
brane is thought to occur through other channels such
as the FadL family of outer membrane proteins (Van den
Berg et al., 2004; Van den Berg, 2005).
We demonstrate that drug packaging in minicells is de-
pendent on both the concentration of drug in the loading
solution, and time of incubation (Figure 2A). The finding
of smooth saturable loading kinetics is consistent with
a normal or ‘‘Langmuir’’ isotherm, suggesting drug loading
via a limited number of uptake sites (Denyer and Maillard,
2002). In addition to providing a barrier to solute entry,
bacterial membranes contain a plethora of transport pro-
teins involved in exporting solutes across their phospho-
lipid bilayer membranes, against a concentration gradient
(Piddock, 2006). Thus, retention of drug in minicells, after
loading, is likely due to the metabolic inactivity that results
from their lack of bacterial genome.
We also demonstrated that bispecific ligands, such as
BsAbs, can be linked to the surface of minicells via the
cell-surface-exposed O-polysaccharide component of
LPS. This enables their specific targeting to cancer cell-
surface receptors, such as EGFR, HER2/neu, CD33, and
CD3. Linkage to O-polysaccharide via the BsAbs is ex-
tremely robust; a factor that likely accounts, in part, for
the efficiency of this cell-targeting approach. In addition,
adhesion of the BsAb/minicell complex to cell-surface re-
ceptors appears to trigger its rapid and efficient endocyto-
sis, with subsequent minicell degradation and liberation of
drug into the cytosol and nucleus, where it exerts its cyto-
toxic effect. As a consequence, targeted minicell-medi-
ated drug delivery resulted in highly significant inhibition
and even regression of tumor growth in vivo in mice with
human breast, ovarian, leukemia, or lung cancer xeno-
grafts. Nonspecific activation of hematopoietic cells by
bacterial products was not sufficient for antitumor effects
since in each xenograft study, nontargeted or nonspecifi-
cally targeted minicells with or without packaged drug did
not result in antitumor effects. Additionally, rapid tumor re-
gression was evident in two dogs diagnosed with NHL
when treated with CD3minicellsDox. This versatility of tar-
geting and of tumor growth inhibition, therefore, are addi-
tional, very favorable features of the minicell drug-delivery
technology. Other approaches to make anticancer mAbs
more effective include conjugation with cell-killing pay-
loads such as anticancer drugs (Saleh et al., 2000; Sievers
et al., 2001) to generate armed antibodies. However, there
is a limitation of four to ten drug molecules that can be
conjugated to an antibody. Our results reveal that an un-
precedented 1 million to 10 million drug molecules can
be packaged within a minicell.
Importantly, minicells were well tolerated with no ad-
verse side effects or deaths in any of the actively-treated
animals, despite repeat dosing. Given that the minicells
are of bacterial origin, it is necessary to be cautious with
parenteral administration since bacterial products are
known to elicit potent inflammatory responses activated442 Cancer Cell 11, 431–445, May 2007 ª2007 Elsevier Inc.by Toll-like receptors (Shizuo and Takeda, 2004). We
have therefore developed a robust minicell purification
procedure to eliminate free endotoxin and free bacterial
components. Interestingly, in the two dogs and three
pigs studied, only the latter demonstrated a very short
lived and mild TNFa response. This contrasts with TNFa
levels as high as 20,000 pg/ml after i.v. injection of
2 mg/kg LPS in pigs (Myers et al., 2003). Interestingly, nei-
ther a TNFa response nor an increase in IL-6, another in-
flammatory cytokine, was observed in the tumor-bearing
dogs despite repeat i.v. administration of high doses of
minicells. Additionally, neither the pigs nor the dogs
showed adverse effects in terms of their hematological in-
dices, serum chemistries, food intake, or growth. Although
our in vivo studies reveal weak immunogenicity of domi-
nantminicell-surface exposed antigen, O-polysaccharide,
and that repeat i.v. administration did not result in immune
exclusion of subsequent doses, extensive evaluation of
immunogenicity would be required to determine the na-
ture of humoral and cellular immunity to the vehicle in
both tumor-bearing and naive animals. Similarly, the
safety data in pigs, although encouraging, must be con-
sidered preliminary and, prior to considering the minicell
as a vector for human use, extensive toxicology, in vivo
stability, etc. studies would be required. In recent times,
excellent mouse models of human cancer have been
developed and the above xenograft studies should be
carried out in such models to provide greater insight
regarding the potential and limitations of the minicell
drug-delivery vector.
The most important feature of minicell drug delivery,
however, is its ability to achieve inhibition/regression of tu-
mor growthwith delivery of amounts of drug that aremark-
edly smaller than those required with systemic delivery of
free drug. For example, with delivery of targeted minicells
carrying Dox or Pac, tumor growth inhibition was signifi-
cantly more marked in the xenograft models than with
the administration of 1875-fold and 8000-fold higher
amounts of their respective free drugs. Similarly, tumor
lysis was observed in two NHL dogs despite receiving
25,000-fold and 10,270-fold less Dox via minicell admin-
istration than that normally administered as part of con-
ventional combination therapy. This remarkable efficacy
may be due to the specificity of drug delivery directly
into the target tumor cell. Although case studies in the
two dogs is very encouraging, the data are anectodal
and further dog clinical trial studies would be required. Bi-
odistribution studies in tumor-bearing mice showed that
within 6 hr post-i.v. administration of EGFRminicellsDox,
30% of the injected dose of Dox was found in the tumor,
a result that is consistent with the rapid and highly signif-
icant antitumor effects seen in themouse and dog studies.
At this early time point, significant Dox concentration was
also observed in the spleen, liver, and lungs and is likely to
reflect the excessminicells being taken up by professional
phagocytic cells that predominate in these organs of the
reticuloendothelial system since Dox-associated toxicity
was not observed in these organs in the mouse and dog
studies.
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rently believed to affect tumor targeting by an initial pas-
sive process involving extravasation from the leaky vascu-
lature (pore sizes 200–1.2 mm; Hobbs et al., 1998; Yuan
et al., 1994) that supports the tumor microenvironment.
This is followed by active targeting via cancer cell-surface
receptor engagement and endocytosis (Mamot et al.,
2003). Although it has been shown that the abnormal tu-
mor microenvironment is characterized by interstitial hy-
pertension and that this phenomenon may limit access
of anticancer antibody therapeutics, this does not appear
to be an absolute barrier as is exemplified by immunolipo-
somes (Nielsen et al., 2002) and antibody conjugated to
Quantum Dots (Gao et al., 2004). Similar considerations
are likely to also underlie the antitumor efficacy of mini-
cell-based drug delivery. Moreover, although not specifi-
cally evaluated, the ability to administer very small yet
targeted doses of chemotherapeutics should allow the
therapeutic potential of even highly toxic agents to be
realized, and/or the use of complex combination or
sequential therapy.
EXPERIMENTAL PROCEDURES
Reagents and Minicell Generation Purification, Enumeration,
and Lyophilization
Detailed Supplemental Experimental Procedures (in the Supplemental
Data available with this article online) describe bacterial strains, their
growth, genomic DNA isolation, plasmids and oligonucleotides used
(see Tables S1, S2, and S3) and their purification. Also detailed online
include minicell generation by chromosomal deletion of the minCDE
genes in parental bacteria and minicell purification to homogeneity,
for example, free of contaminating parent bacterial cells, cellular
debris, bacterial blebs, and free endotoxin.
Bispecific Antibody Construction and Tumor Targeting
Bispecific Antibody (BsAb) was constructed by linking an anti-S. Ty-
phimurium O-antigen MAb (IgG1; Biodesign) and a mouse MAb di-
rected against a cancer cell-surface receptor that is either antihuman
EGFR (IgG2a; Calbiochem) or HER2/neu (IgG1; Serotec), or anticanine
CD3 (IgG1; Serotec). Nonspecific BsAb carried an anti-CMV MAb
(IgG2a; DakoCytomation). The two antibodies were crosslinked as de-
tailed in the Supplemental Experimental Procedures online, via their Fc
regions using purified recombinant protein A/G (Pierce Biotechnol-
ogy), which results in BsAb as well as multimeric complexes. The
BsAb was incubated with minicells for 1 hr at room temperature to en-
able BsAb binding to the minicell surface exposed O-polysaccharide.
Excess unbound BsAb was removed by filtration through 0.2 mm filter
(PALL). Approximately 5 mg of the BsAb complex was sufficient to
saturate 109 minicells.
Cancer Cell Lines and Drug Packaging in Minicells
Chemotherapeutic drugs, Dox and Pac, were dissolved in sterile phys-
iological saline and in 50:50 (v:v) Cremophor EL:ethanol, respectively
(Sigma). Pac solution was diluted 1:5 in 0.9% saline immediately be-
fore injection. MDA-MB-468 breast, SKOV-3 ovarian, A549 lung, and
HL-60 promyelocytic leukemia cancer cell lines (ATCC) were cultured
in RPMI-1640 medium (Gibco) supplemented with 10% FBS, 2 mM L-
glutamine, and 100 U/ml of both penicillin G and streptomycin. Liposo-
mal-Dox (DOXIL) was purchased fromOrtho Biotech. Purifiedminicells
were packaged with chemotherapeutic drugs by incubating minicells
at 37C overnight with each drug, where the external loading concen-
tration ranged from 10 to 400 mg/ml. Oregon Green 488-conjugated
Pac and BODIPY FL-conjugated vinblastine were initially dissolved inethanol and methanol, respectively, followed by dilution in BSG.
Post-drug loading into minicells, excess drug was removed by Amicon
stirred-cell ultrafiltration (Millipore; 300 kDa cut-off filter) with six
washes of sterile BSG. Drug extraction from packaged minicells in-
volved five cycles of vortexing and sonication in the presence of
97mMHCl-isopropyl alcohol (HCl-IPA). The sampleswere then diluted
in an equal volume of water and the five cycles were repeated. After
centrifugation at 13,200 rpm for 5min to pellet debris, the supernatants
were harvested for drug quantitation, as detailed in the Supplemental
Experimental Procedures online.
Electron and Fluorescence Microscopy of Minicells
minCDE mutant bacterial strains and purified minicells were pro-
cessed for scanning and transmission EM using established protocols.
Sections for TEM were visualized using a Hitachi H-7000 transmission
electron microscope (ICPMR, Westmead Hospital, Sydney, Australia).
Digital images were recorded using an AnalySis MegaView II widefield
CCD camera. SEM specimens were examined using a Hitachi S-900
Field Emission scanning electron microscope. Samples were pro-
cessed for immunogold-TEM using the freeze-substitution method
(Riegman et al., 1988) and labeling minicells with anti-S. Typhimurium
O-antigen (Factor 4, Group B specificity; Abbott Murex) mAb (1:200),
followed by gold (10 nm)-conjugated secondary antibody. Samples
were analyzed using a Philips CM-120 BioTWIN electron microscope
at 80 kV. Images were captured onto type 4489 Kodak EM emulsion
film. Fluorescence microscopy images of Minicells were captured us-
ing a Leica DMLB fluorescent microscope with an Olympus DP70
camera and DP controller/camera software. Pac fluorescence was
viewed using the Leica GFP filter. Images showing the minicell-cancer
cell interactions were captured using the IX81 confocal microscope
(Olympus) and the CellR software.
Drug Quantitation Using HPLC, LC-MS, and ICP-MS
Drugs extracted fromminicells were quantitated based on HPLC-fluo-
rescence peak and LC-MS/MS or ICP-MS (Inductively coupled plasma
mass spectrometry) analyses as previously described for Dox (Zheng
et al., 2001; Cummings, 1985) and Pac (Sharma et al., 1997; Larson
et al., 2003). HPLC analysis was performed on a Shimadzu 10AVP
system incorporating a RF-10A XL fluorescence detector. Detailed
extraction, analysis, and quantitation procedures for Dox, irinotecan,
cisplatin, and Pac are provided in the Supplemental Experimental
Procedures online.
In Vitro Cytotoxicity Assay and Tumor Xenograft Studies in Nude
Mice
In vitro cytotoxicity was evaluated using the CellTiter 96 Aqueous One
Solution Cell Proliferation Assay (Promega), according to themanufac-
turer’s instructions. Athymic (nu/nu) mice (4–6 weeks old) were pur-
chased from the Animal Resources Centre, Perth, WA, and all animal
experiments were performed in compliance with National Health and
Medical Research Council, Australia, guidelines for the care and use
of laboratory animals andwith EnGeneIC Animal Ethics Committee ap-
proval. MDA-MB-468, SKOV-3, A549, and HL-60 human tumor cell
lines were cultured and 1.5 3 106 cells in 50 ml serum-free media to-
gether with 50 ml growth-factor-reduced matrigel (BD Biosciences)
were injected subcutaneously between the shoulder blades. Tumor
volume (mm3) was determined by measuring length (l) and width (w)
and calculating volume (V = lw2/2) as described (Sun et al., 1999).
Experimental and control treatments were carried out once the tumor
volumes were between 50 and 80 mm3, at which time the tumor mass
was clearly palpable and vascularized as determined following exci-
sion and microscopic observation of tumors. Mice were randomized
to different groups prior to various treatments. All tumor volume mea-
surements were performed by an investigator who was blinded to the
treatments administered. Statistical analysis was performed by analy-
sis of variance (ANOVA), with p < 0.05 being considered significant.Cancer Cell 11, 431–445, May 2007 ª2007 Elsevier Inc. 443
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Biodistribution of minicellsDox was determined in two separate exper-
iments in mice with MDA xenografts. When the tumor volume reached
140–170 mm3 (experiment 1) or 400–600 mm3 (experiment 2), mice
were randomly divided into three groups (G1, G2, and G3) of nine
mice per group, which received i.v. either free Dox (150 mg/dose), mini-
cellsDox or
EGFRminicellsDox (74 mg Dox/dose contained in 5 3 109
minicells), respectively. Posttreatment, three mice from each group
were euthanized at 6 and 24 hr and plasma and tissue was harvested,
frozen, and lyophilized for extraction and determination of Dox con-
centration using ESI and Maldi and LC-MS/MS as detailed in the Sup-
plemental Experimental Procedures online. Biodistribution of minicells
was determined by radioiodinating anti-EGFR/anti-LPS or anti-CMV/
anti-LPS BsAbs prior to minicell surface O-polysaccharide attach-
ment. The minicells were administered i.v. into nude mice bearing
MDA-MB-468 xenografts. Five mice from each group were euthanized
at 2, 6, and 24 hr posttreatment and tumor, spleen, liver, kidney, and
lungswere excised from eachmouse. The organswerewashed in ster-
ile saline and weighed, and radioactivity was determined using a
Wallac Wizard 1470 Automatic Gamma Counter. Detailed methods
are described in the Supplemental Experimental Procedures online.
Two dogs with biopsy-proven T cell NHL were treated with CD3mini-
cellsDox, which targeted the canine CD3 T cell surface receptor as de-
tailed in the Supplemental Experimental Procedures online. The dogs
were treated at the Brisbane Veterinary Specialist Centre (Australia)
with the owners’ consent.
The safety ofminicellswasdetermined in three largewhite Landrey3
Durock pigs that were given 5 3 109 minicells i.v. through ear vein
catheter as detailed in the Supplemental Experimental Procedures
online. The study was carried out at the University of Sydney with the
approval of the animal ethics committee.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures and three supplemental tables and can be found with this article
online at http://www.cancercell.org/cgi/content/full/11/5/431/DC1/.
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